Advanced search
Publication Cover
Platelets Volume 11, 2000 - Issue 3
Submit an article Journal homepage
14
Views
11
CrossRef citations to date
0
Altmetric
Research Article

An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models

I.A. Jagroop, D.P. Mikhailidis Department of Molecular Pathology and Clinical Biochemistry, Royal Free and University College Medical School (University of London), Royal Free campus, London, UK.
Pages 161-165 | Published online: 07 Jul 2009

  • Kissebah AH, Freedman DS, Peins AN. Health risks of obesity. Mod Clin N Am 1989+ADs- 73: 111-38.
  • Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MI, Wood JL. The effect of age on the association between body-mass index and mortality. New Engl J Med 1998+ADs- 338: 1-7.
  • Guerra MJ, Liste I, Labandeira-Garcia JL. Interaction between the serotonergic, dopaminergic, and glutamatergic systems in fenfluramine-induced Fos expression in striatal neurones. Synapse 1998+ADs- 28: 71-82.
  • Campbell DB. Dexfenfluramine: an overview of its mechanisms of action. Rev Contemp Pharmacother 1991+ADs- 2: 93-113.
  • McCann UD, Yuan J, Hatzidimitriou G, Ricaurte GA. Selective serotonin reuptake inhibitors dissociate fenfluramine's anoretic and neurotoxic effects: importance of dose, species and drug. J Pharm Exp Ther 1997+ADs- 281: 1487-98.
  • Kurz X, Van Ermen A. Valvular heart disease associated with fenfluramine-phentermine. New Engl J Med 1997+ADs- 337: 1172-3.
  • Robiolio PA, Rigolin VH, Wilson JS, Harrison JK, Sanders LL, Bashore TM, Feldman JM. Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995+ADs- 92: 790-5.
  • Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993+ADs- 70: 537-41.
  • McMurray I, Bloomfield P, Miller HC. Irreversable pulmonary hypertension after treatment with fenfluramine. Br Med J 1986+ADs- 292: 239-40.
  • Abenhaim L, Monde Y, Brenot F, Rich S, Benichiou J, Kurz X, Higenbottam T, Oakley C, Waiters E, Aubier M, Simmonneau G, Begaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. New Engl J Med 1996+ADs- 335: 609-16.
  • Weir EK, Reeve HL, Huang JM, Michelakis E, Nelson DP, Hampl V, Archer SL. Anoretic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 19+ACUAOw- 94: 2216-20.
  • Barradas MA, Mikhailidis DP. The use of platelets as models for neurones: possible applications to the investigation of eating disorders. Biomed Pharmacother 1993+ADs- 47: 11-18.
  • Blundell JE. Serotonin and appetite. Neuropharmacology 1984+ADs- 23: 1537-51.
  • Samanin R, Grattini S. The pharmacology of serotonergic drugs affecting appetite. In: RJ Wurtman, JJ Wurtman, eds. Nutrition and the brain. New York: Raven Press 1990+ADs- 8: 163-92.
  • Barradas MA, O'Donoghue S, Mikhailidis DP. Measurement of platelet volume using a channelyzer: assessment of the effect of agonists and antagonists. In Vivo 1992+ADs- 6: 629-34.
  • Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Hartzell VS. Valvular heart disease associated with fenfluramine-phentermine. New Engl J Med 1997+ADs- 337: 581-8.
  • IA Jagroop, I Clatworthy, J Lewin, DP Mikhailidis. Shape change on human platelets-measurements with a channelyzer and visualisation by electron microscopy. Platelets 2000+ADs- 11: 28-32.
  • Schachter M, Grahame-Smith DG. 5-Hydroxytryptamine and the platelet: specific binding and active uptake. In: De Clerck F, Vanhoutte PM, eds. 5-Hydroxytryptamine in peripheral reactions. New York: Raven Press, 1982: 49-59.
  • Barradas MA, Mikhailidis AM, Mikhailidis DP, Dandona P. The Effects of fenfluramine on in vitro platelet aggregation. Br J Clin Pharm 1982+ADs- 14: 466-7.
  • Barradas MA, Mikhailidis DP, Dandona P. The effect of collageninduced platelet aggregation in vitro. Br J Clin Pharm 1983+ADs- 16: 459.
  • Douglas JG, Munro JF, Kitchin AH, Muir AL, Proudfoot AT. Pulmonary hypertension and fenfluramine. Br Med J 1981+ADs- 283: 881-3.
  • Anonymous. Fenfluramine (Ponderax Pacaps), dexfenfluramine (Adifax) and pulmonary hypertension. Current Problems - Committee on Safety of Medicine 1992: 34.
  • Breuer J, Georgaraki A, Siieveerding L, Baden W Apitz J. Increased turnover of serotonin in children with pulmonary hypertension secondary to congenital heart disease. Pediatr Catdiol 1996+ADs- 17: 214-9.
  • Vivero LE, Anderson PO, Clark RF. A close look at fenfluramine and dexfenfluramine. J Emerg Med 1998+ADs- 16: 197-205.
  • Eddahibi S, Raffestin B, Pham I, Launay JM, Aegerter P, Sitbon M, Adnot S. Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Am J Physiol 1997+ADs- 272: 1173-81.
  • Zinner MJ, Kasher F, Jaffe BM. The haemodynamic effects of intravenous infusion of serotonin in conscious dogs. J Surg Res 1983+ADs- 34: 171-8.
  • Anonymous. MMWR Morbid Mortal Weekly Rep, November 1997.
  • Shiverly BK, Roldan CA, Gill EA, Najarian T, Loar SB. Prevalence and determinants of valvulopaty in patients treated with dexfenfluramine. Circulation 1999+ADs- 100: 2161-7.
  • Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern tied 1992+ADs- 11: 50-2.
  • Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pilot HC, Kvols LK. Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients. Circulation 1993+ADs- 87: 1188-96.
  • Barradas MA, Gill DS, Fonseca VA, Mikhailidis DP, Dandona P. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest 1988+ADs- 18:399-404.
  • Gregorini L, Marco J, Fajadet J, Demies M, Cassagneau B, Brunei P, Bossi IM, Mannucci PM. Ticolpidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. J Am Coll Cardiol 1997+ADs- 29: 13-20.
  • Mikhailidis DP, Barradas MA, Jeremy JY, Gracey L, Wakeling A, Dandona P. Heparin-induced platelet aggregation in anorexia nervosa and in severe peripheral vascular disease. Eur J Clin Invest 1985+ADs- 15: 313-9.
  • Caplice NM, Aroney CN, Bett JHN, Cameron J, Campbell JH, Hoffman N, McEniery PT, West MJ. Growth factors released into the coronary circulation after vascular injury promote proliferation of human vascular smooth muscle cells in culture. J Am Coll Cardiol 1997+ADs- 29: 1536-41.
  • Cheshire NJW, Wolfe JHN, Barradas MA, Chambler AW, Mikhailidis DP. Smoking and plasma fibrinogen, lipoprotein (a) and serotonin are markers for postoperative infrainguinal graft stenosis. Eur J Vase Endovasc Surg 1996+ADs- 11: 479-86.
  • Fawcett A, Jagroop A, Si an M, Nott DM, Springall RG, Mikhailidis DP. Platelet activation and serotonin release during colorectal surgery. Platelets 1998+ADs- 9: 109-13.
  • Jagroop IA, Barradas MA, Mikhailidis DP. A low molecular weight heparin, nadroparin (Fraxiparine), inhibits thrombin induced platelet shape change and does not enhance spontaneous platelet aggregation. Br J Clin Pharmacol 1996+ADs- 41: 163-5.
  • Barradas MA, Jagroop IA, O'Donoghue S, Jeremy JY, Mikhailidis DP. Effect of milrinone on human platelet shape change, aggregation and thromboxane A2 synthesis: an in vitro study. Thromb Res 1993+ADs- 71: 227-36.
  • Nystrom ML, Barradas MA, Mikhailidis DP. N-Formyl-methionine-leucine-phenylalanine +AFs-fMLP+AF0-, a bacterial chemotactic peptide, stimulates platelet shape change in human whole blood. Platelets 1993+ADs- 4: 156-8.
  • Nystrom ML, Barradas MA, Jeremy JY, Mikhailidis DP. Platelet shape change in whole blood: differential effects of endotoxin. Thromb Haemost 1994+ADs- 71: 646-50.
  • Whitworth NH, Barradas MA, Mikhailidis DP, Dandona P. An investigation into the effects of bacterial lipopolysaccharide on human platelets. EurJ Haematol 1989+ADs- 43: 112-9.
  • Mikhailidis DP, Barradas MA, O'Donoghue S, Dandona P. Evidence for in vivo platelet activation following the injection of conventional unfractionated heparin. Platelets 1990+ADs- 1: 189-92.
  • Barradas MA, Jeremy JY, Mikhailidis DP. The effect of a novel (; 12 antagonist, L-659,066, and of yohimbine on human platelet aggregation and TXA2 synthesis. J Drug Dev 1990+ADs- 3: 37-46.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.